Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

K Ray K; E Bruckert; B van Hout; M Tepie; I Feudjo Bridges; M Sibartie

Conference Papers Year : 2020

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

, (1, 2) , , , ,

1
2

K Ray K

Function : Author

E Bruckert

Function : Author

Service d' Endocrinologie

Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases

B van Hout

Function : Author

M Tepie

Function : Author

I Feudjo Bridges

Function : Author

M Sibartie

Function : Author

Domains

Life Sciences [q-bio]

Maryse Guerin : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03970199

Submitted on : Thursday, February 2, 2023-4:08:19 PM

Last modification on : Thursday, February 15, 2024-3:00:09 PM

Dates and versions

hal-03970199 , version 1 (02-02-2023)

Identifiers

HAL Id : hal-03970199 , version 1

Cite

K Ray K, E Bruckert, B van Hout, M Tepie, I Feudjo Bridges, et al.. Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study. European-Society-of-Cardiology (ESC) Congress, Aug 2020, Amsterdam, Netherlands. ⟨hal-03970199⟩

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

Domains

Dates and versions

Identifiers

Cite

Export

Collections

Share